A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis

To join this study, people must be between 18 and 65 years old and have a confirmed diagnosis of Secondary Progressive Multiple Sclerosis (SPMS). It's important that you haven't had any new MS attacks or relapses in the last two years, and your disability has shown some progression in the past year.

There are also reasons why someone might not be able to join. For example, if you can't have an MRI scan because of certain medical conditions (like some metal implants) or if you have other serious health issues that might interfere with the study. If you are a woman who could become pregnant, you would need to use effective birth control throughout the study. Heavy drinking or drug use, or other serious mental health conditions, would also prevent you from taking part.

If you decide to take part in this study, you would first go through a screening process to check if you're suitable. Once you're in, you'll be randomly assigned to either receive remibrutinib or a placebo (a dummy drug) for the first part of the study. Neither you nor the study team will know which one you are getting. After this initial 'blinded' period, everyone will then get the chance to receive remibrutinib openly.

Throughout the study, you'll have regular hospital or clinic visits. During these visits, you'll likely have physical exams, blood tests, and MRI scans to monitor your health and see how the medication is affecting your MS. The doctors will also ask you questions about your symptoms and how you're feeling. The study is designed to continue until a certain number of progression events have occurred in the study group, which means the total duration could vary and will be explained by the study team.